CTU: A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants with BCG-naïve High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC)

  • Patel, Manish (Primary Chief Investigator)
  • Chester, Catherine (Clinical Trial Unit Staff)
  • Chapman, Nicola (Clinical Trial Unit Staff)
  • Contacos, Christine (Clinical Trial Unit Staff)

Project: Research

Project Details

Short title17000139BLC3002
AcronymSunRISe-3
StatusActive
Effective start/end date24/05/23 → 11/05/28